Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04379843 · ClinicalTrials.gov registry record
The Efficacy of Implementing a Treatment Algorithm in Managing Patent Ductus Arteriosus (PDA) in the Extremely Low Birth Weight Neonatal Population.
A clinical trial, sponsored by Pediatrix.
- Completed
- Registry status
- 208
- Enrollment target
NCT04379843: Completed study, sponsored by Pediatrix.
NCT04379843 is a clinical trial that has completed, run by Pediatrix. The registered enrollment target is 208 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04379843 has completed, sponsored by Pediatrix.
- COMPLETED
- Registry status
- 208 participants
- Enrollment target
Study Summary
To evaluate whether utilizing a standardized patent ductus arteriosus (PDA) treatment algorithm in managing ELBW (extremely low birth weight) neonates ≤1000 grams (g) improves clinical outcomes and helps prevent undesirable side effects from PDAs.
Primary Outcome
\- Number of ventilation days {requirement of respiratory support of nasal continuous positive airway pressure (CPAP) or greater}
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2016-07-27 |
| Est. Completion | 2021-07-31 |
What the finished NCT04379843 record still lists
NCT04379843 is an observational study that tracks outcomes without assigning an intervention. The registered 208 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04379843 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04379843 about?
NCT04379843 is a clinical study titled "The Efficacy of Implementing a Treatment Algorithm in Managing Patent Ductus Arteriosus (PDA) in the Extremely Low Birth Weight Neonatal Population.". To evaluate whether utilizing a standardized patent ductus arteriosus (PDA) treatment algorithm in managing ELBW (extremely low birth weight) neonates ≤1000 grams (g) improves clinical outcomes and helps prevent undesirable side effects from PDAs.
What is the current status of trial NCT04379843?
This trial is currently completed. The enrollment target is 208 participants. The study started on 2016-07-27. Estimated completion is 2021-07-31.
Who is sponsoring clinical trial NCT04379843?
This trial is sponsored by Pediatrix, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465774 · 208 participants
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
- NCT03803332 · 208 participants · NA
A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel
- NCT04732065 · 208 participants · Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- NCT05293756 · 208 participants · NA
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI